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Abstract The transactivation potential of Nm23-H1, a homo-
log of c-myc transcription factor Nm23-H2/PuF was assessed in
yeast as a fusion protein with the DNA binding domains (DBDs)
of GAL4 and LexA. The C-terminal half of Nm23-H1 exhibited
strong transactivation of the reporter genes, LacZ and Leu2
carrying GAL4 and LexA upstream activating sequences
(UASs), whereas the full-length Nm23-H1 and its N-terminal
did not. Similar results were also obtained with Nm23-H2/PuF
transactivating the reporter genes only by the C-terminus fused
to GAL4 and LexA DBDs. Hence, our results suggested a
possible regulatory role of the N-termini of Nm23 isotypes upon
transactivation.
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1. Introduction
Nm23-H1 was ¢rst identi¢ed as a tumor metastasis suppres-
sor [1]. The inverse relationship between the metastatic poten-
tial and the level of Nm23-H1 expression was well established
in various cancers [2^4]. Nm23-H1 and its homolog proteins
are well conserved from Escherichia coli to human. These
proteins have NDP kinase activities catalyzing ATP-depend-
ent synthesis of nucleoside triphosphates from their corre-
sponding nucleoside diphosphates [5]. Nm23 homologs in var-
ious higher eukaryotes have been proposed to retain
multifunctional properties. Involvements of Nm23 homologs
in various cellular processes, such as stimulating transcription
[6,7], cell di¡erentiation and proliferation [8,9], and apoptosis
[10] have been described. In addition, a serine/threonine spe-
ci¢c protein phosphotransferase activity [11,12] and a histidine
protein kinase activity [13] were also shown to be detected.
In human, four Nm23 isotypes, Nm23-H1, Nm23-H2, DR-
Nm23 and Nm23-H4 are known to date [10,14^16]. Among
them, Nm23-H1 and Nm23-H2 shared highest amino acid
homology [15] and coexist as heterohexamers [17^19]. How-
ever, these two isotypes have been considered to participate in
di¡erent cellular processes. Nm23-H1 has demonstrated a
metastasis suppressor function whereas Nm23-H2 has not.
Nm23-H2 was proved to be identical to PuF, a transcription
factor of c-myc proto-oncogene [6], but Nm23-H1 failed to
bind to the c-myc promoter [20]. Recombinant Nm23-H2/PuF
made from E. coli was able to bind to the nuclease-hyper-
sensitive element within the c-myc promoter [7] and a single-
stranded polypyrimidine-rich DNA and RNA [20] in vitro.
Considering high homology to Nm23-H2/PuF, it was of
much interest whether Nm23-H1 might function as a tran-
scription factor. However, a direct test of DNA binding ca-
pacity of Nm23-H1 was not possible since no target sequence,
if any, was identi¢ed yet. Thus, we assessed a transactivation
potential of Nm23-H1 with creating fusion proteins to the
known DNA binding domains with the aid of yeast genetic
system. As well, in order to minimize the artifacts as a fusion
protein, two independent assay systems, GAL4- [21,22] and
LexA-based [23] systems, were used.
2. Materials and methods
2.1. Materials, media, strains, and plasmids
All chemicals used for yeast transformation and L-galactosidase
assays were purchased from Sigma (St. Louis, MO). Restriction en-
zymes, ligase, and Klenow fragment were obtained from Promega
(Madison, WI). Synthetic dropout minimal (SD) medium with various
supplements was used for yeast culture, maintenance, and selection of
transformants [24]. Yeast strains, Y187 (MatK, ura3-52, his3-200,
ade2-101, trp1-901, leu2-3, 112, gal4v, met-, gal80v, URA3: :GA-
L1UAS-GAL1TATA-lacZ), and EGY48 (Mata, ura3-52, his3, trp1,
leu2: :pLeu2-LexAop6/pSH18-34 (LexAop-lacZ)) were obtained from
Clontech Laboratories, Inc. (Palo Alto, CA). As yeast-E. coli shuttle
vectors, pGBT9 carrying yeast GAL4 DBD [25] and pLexA contain-
ing E. coli LexA DBD sequences [26] were purchased from Clontech
Laboratories, Inc. as parts of the MatchMaker two-hybrid assay kits.
Plasmids pET3C-nm23-H1 and pET3C-nm23-H2 [27,28] carrying the
coding sequences of nm23-H1 and nm23-H2, respectively, were kindly
provided by Dr. P.S. Steeg (NIH, USA).
2.2. Construction of vectors expressing the Nm23-H1 and the Nm23-H2
full-size or truncated proteins fused to GAL4 and LexA DNA
binding domains
The NdeI-BamHI fragments from the pET3C-nm23-H1 and the
pET3C-nm23-H2 corresponding to the Nm23-H1 and the Nm23-H2
coding regions, respectively, were inserted into SmaI and BamHI
double digested pGBT9. The NdeI sites of the inserts were ¢lled-in
with Klenow enzyme to generate in-frame fusion to the GAL4 DBD.
The resulting plasmids were named pT9H1 and pT9H2, respectively.
The correct reading frames for expressing Nm23-H1 and Nm23-H2 in
pT9H1 and pT9H2 were veri¢ed by sequencing. For the construction
of N-terminal halves (1 to 76 amino acids of total 152 amino acids) of
Nm23-H1 and Nm23-H2, pT9H1 and pT9H2 were cut with NcoI/
BamHI enzymes, then the larger fragment was religated after ¢lling-
in the protruding both ends with Klenow enzyme. Similarly, in order
to get the C-terminal halves (76 to 152 amino acids), each of the larger
NcoI/EcoRI fragments of pT9H1 and pT9H2 was rejoined after Kle-
now ¢ll-in, creating in-frame fusion with the GAL4 DBD coding
region. These plasmids were called pT9H1N (producing the N-termi-
nal half of Nm23-H1 fused to GAL4 DBD), pT9H2N (N-terminal
half of Nm23-H2), pT9H1C (C-terminal half of Nm23-H1), and
pT9H2C (C-terminal half of Nm23-H2).
For the LexA based assay alternative to the Gal4 system, plasmids
pLexH1 and pLexH2 were constructed by inserting the 0.5 kb EcoRI-
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SalI fragments containing the Nm23-H1 and the Nm23-H2 coding
sequences from pT9H1 and pT9H2 into EcoRI/SalI double digested
pLexA vector, respectively. The N-terminal and C-terminal halves of
Nm23-H1 and Nm23-H2 fused in-frame to the LexA DBD were also
constructed by Klenow ¢ll-in/ligation of the larger NcoI/SalI or NcoI/
EcoRI fragments of pLexH1 and pLexH2. These were named
pLexH1N (N-terminal half of Nm23-H1 fused to GAL4 DBD),
pLexH1C (C-terminal half of Nm23-H1), pLexH2N (N-terminal
half of Nm23-H2), and pLexH2C (C-terminal half of Nm23-H2).
The correct reading frames were con¢rmed by sequencing.
2.3. Yeast transformation and L-galactosidase assay
The lithium acetate method for preparing yeast competent cells [29]
was adopted to introduce the various constructs into yeast. Trans-
formants were selected on SD medium lacking proper supplements
as indicated in each case below.
The L-galactosidase enzyme assays of colony-lift ¢lters [21] and of
liquid cultures using o-nitrophenyl L-D-galactopyranoside (ONPG) as
a substrate [30] were carried out according to the instructions from
Clontech Laboratories, Inc. In the plate L-galactosidase assay for a
blue/white detection directly on SD medium lacking uracil and histi-
dine for pLexA derived constructs, 5-bromo-4-chloro-3-indolyl-D-ga-
lactopyranoside (X-gal) was added at a concentration of 40 mg/l to
melted SD medium (48‡C). Blue colors on the colony-lift ¢lters and
on the plates containing X-gal were judged after 3 days at 30‡C.
3. Results
3.1. Transactivation of the lacZ reporter gene by the
C-terminal half of Nm23-H1 in the Gal4 based assay
system
Transactivation of the lacZ reporter gene with GAL4 UAS
was tested by introducing fusion proteins of Nm23-H1 with
GAL4 DBD in yeast cells. Various plasmids expressing either
full-size (namely, pT9H1), N-terminal half (pT9H1N) or C-
terminal half (pT9H1C) of the Nm23-H1 were transformed
into yeast host Y187, and then the transformants selected
on SD medium depleted tryptophan were assayed for the L-
galactosidase enzyme activity. For the comparison, similar
constructs, namely pT9H2, pT9H2N and pT9H2C made for
Nm23-H2 were also transformed. Such fusion proteins can
speci¢cally bind to the upstream region of the lacZ reporter
gene.
In the colony-lift L-galactosidase ¢lter assay for a blue/
white color detection, the transformants of pT9H1 and
pT9H1N exhibited white color. On the contrary, blue color
was developed in a short time in the transformants of
pT9H1C producing truncated Nm23-H1 proteins having the
C-terminal half (data not shown because of color prints).
Comparable results were obtained in the transformants ex-
pressing the Nm23-H2/Gal4 fusion proteins, showing blue
colors also only in the transformants of pT9H2C producing
the C-terminal half of Nm23-H2. For the quantitative com-
parison, the liquid L-galactosidase assay using ONPG as a
substrate was applied to those transformants. As shown in
Fig. 1, L-galactosidase units in the transformant of pT9H1C
were signi¢cantly increased (P6 0.01) more than 10-fold com-
pared to those detected in transformants of pT9H1 and
pT9H1N showing the negative control level (see also Table
1). Similar results were also obtained with Nm23-H2 (Fig. 1).
Even though the C-terminal half of Nm23-H2 transactivated
the reporter gene less strongly than that of Nm23-H1, yet
higher than those found in the full-size and the N-terminal
half of Nm23-H2 proteins (P6 0.01). Blue signals for the
evidence on transactivation of the reporter gene by the full-
size proteins of Nm23-H1 and Nm23-H2 were absent or too
weak to detect.
3.2. Transactivation of the lacZ reporter gene in the LexA
based assay system by the Nm23-H1 C-terminus
To con¢rm the observed results and exclude the possible
artifacts in the Gal4 based assay, fusion proteins of Nm23-
H1 as well as Nm23-H2 to LexA DBD were expressed and
tested for transactivation of the lacZ reporter gene having
LexA UAS in yeast. The transformants of pLexH1 producing
the full-length Nm23-H1 with LexA DBD, pLexH1N (N-ter-
minal halves), and pLexH1C (C-terminal halves) were selected
on SD medium without uracil and histidine. Comparable con-
structs of pLexH2, pLexH2N, and pLexH2C for Nm23-H2
were also transformed into EGY48. Then, the L-galactosidase
enzyme assay for color developments was carried out on SD
plates containing X-gal. Similarly shown in the Gal4 based
assay, only the transformants of pLexH1C as well as
pLexH2C expressing the C-terminal half of each protein
turned blue, while colonies of pLexH1 and pLexH2 producing
the full-length proteins remained white (data not shown).
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Fig. 1. Di¡erential transactivation potentials of the truncated versus
the full-size Nm23 isotypes in GAL4 system. The liquid L-galacto-
sidase assay was carried out in the transformants of yeast strain
Y187 expressing the fusion proteins of GAL4 DBD with Nm23-H1
full size (from pT9H1), Nm23-H1 N-terminus (pT9H1N), Nm23-H1
C-terminus (pT9H1C), Nm23-H2 full size (pT9H2), Nm23-H2 N-
terminus (pT9H2N), and Nm23-H2 C-terminus (pT9H2C). One unit
of L-galactosidase activity was de¢ned as the amount of enzyme re-
quired to hydrolyze 1 Wmol of ONPG to o-nitrophenol and D-galac-
tose per minute. The average values with standard errors of L-galac-
tosidase units were indicated based on the ¢ve sets of independent
experiments. Each set assaying L-galactosidase activities of the six
kinds of transformants plus a negative control (Y187) was carried
out at the same time. Duplicate measurements for each sample were
performed.
Table 1
Fold di¡erences of L-galactosidase unit in the various transformants compared to that of host cells, Y187 for the GAL4 and EGY48 for the
LexA based systems
Host cell H1 H1N H1C H2 H2N H2C
GAL4 system 1 1.5 1.4 12 1.4 1.3 6
LexA system 1 2.1 5.4 523 3.2 7.4 116
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Such di¡erences were clear and extreme in the liquid L-galac-
tosidase assay (Fig. 2). More than 100^250-fold increase for L-
galactosidase enzyme units was demonstrated in the trans-
formants of pLexH1C compared to those detected in the
transformants of pLexH1N and pLexH1 (Table 1). The trans-
activation of the LacZ reporter was driven more strongly
(more than 7-fold increase) by the C-terminus of Nm23-H1
than by the B42, a weak activator domain derived from bac-
teria fused to LexA [31], as a positive control for transactiva-
tion (Fig. 2). Again, activation of the lacZ gene by the full
length of Nm23-H1 and Nm23-H2 fused to LexA DBD was
not able to be detected. In addition, much higher transactiva-
tion of the lacZ were exhibited in the transformants of
pLexH1C compared to that of pLexH2C (P6 0.01).
3.3. Transactivation of the Leu2 reporter gene by the
C-terminal half of Nm23-H1 in the LexA system
The yeast strain, EGY48 has dual reporter genes, the LacZ
within the pSH18-34 plasmid and the yeast LEU2 with LexA
operators integrated into yeast chromosome. Without tran-
scriptional stimulation of the Leu2 gene, the transformants
with pLexA derived plasmids could not grow on SD lacking
leucine. Fig. 3 showed the transformants of pLexH1,
pLexH1N, and pLexH1C grown on SD medium lacking uracil
and histidine for positive growth (Fig. 3A) and SD medium
depleting uracil, histidine, and leucine to check transactivation
of the Leu2 reporter (Fig. 3B). Full growth of pLexH1C trans-
formants on the medium without leucine (Fig. 3B; bottom-
left) indicated strong transactivation of the Leu2 reporter gene
by the Nm23-H1 C-terminal half. Growth of the transform-
ants of pLexH1 was hardly detected (see Fig. 3B; top-left),
implying no transactivation of Leu2 gene by the full-size
Nm23-H1 proteins. In the case of transformants of pLexH1N
expressing N-terminal halves of Nm23-H1 fused to LexA
DBD, colonies grew very slowly and eventually can be seen
as spots after 4^6 days on SD medium lacking leucine (Fig.
3B; middle-left). Similar results for Nm23-H2/PuF’s transac-
tivation of the Leu2 reporter (see Fig. 3; right-half of the
plates) were demonstrated in the transformants of pLexH2
(top-right), pLexH2N (middle-right), and pLexH2C (bot-
tom-right) producing the full-length, N-terminal, and C-termi-
nal halves of Nm23-H2, respectively.
4. Discussion
The fusion proteins of Nm23 with the well characterized
DBDs such as the yeast GAL4 and the E. coli LexA were
expressed in suitable hosts carrying the reporter genes of
LacZ and Leu2 with GAL4 and LexA UASs, in order to
test whether the human Nm23-H1 possesses a transactivation
domain. From the assays using two alternative Gal4 and
LexA based systems, clearly we obtained the consistent re-
sults : (1) the truncated protein having only the C-terminal
half of Nm23-H1 was able to transactivate the reporter genes,
and (2) the full-length Nm23-H1 failed to transactivate the
reporters or transactivated too weak to detect. Results ob-
tained here suggested the possibility of Nm23-H1 as a puta-
tive transcription factor comparable to Nm23-H2/PuF, even
though both of the full-length Nm23 isotypes were not able to
stimulate transcription of the reporters. Apparently, deletion
of the N-terminal halves unmasked the potential transactiva-
tion capability of Nm23 proteins.
A negative e¡ect upon transactivation by the full length of
both proteins was not due to the lack of expression of both
proteins and the failure of nuclear translocation. In the yeast
two-hybrid assay, cotransformants of the Nm23-H1/GAL4
DBD fusion vector (pT9H1) and the Nm23-H2/GAL4 activa-
tion domain (AD) fusion vector showed blue color on X-gal
plates (data not shown). Similarly, cotransformation of the
Nm23-H2/GAL4 DBD fusion vector (pT9H2) and the
Nm23-H1/GAL4 AD fusion vector gave the same result.
These positive signals not only demonstrated the protein in-
teractions between Nm23-H1 and Nm23-H2 but also pro-
vided the evidence of the proper expressions and nuclear
translocations of both Nm23 isotypes.
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Fig. 2. Di¡erential transactivation potentials of Nm23 domains. The
liquid L-galactosidase assay was performed in the transformants of
yeast strain EGY48 producing fusion proteins of LexA DBD with
Nm23-H1 full size (from pLexH1), Nm23-H1 N-terminus
(pLexH1N), Nm23-H1 C-terminus (pLexH1C), Nm23-H2 full size
(pLexH2), Nm23-H2 N-terminus (pLexH2N), and Nm23-H2 C-ter-
minus (pLexH2C). The average values with standard errors of L-ga-
lactosidase units were indicated based on the ¢ve sets of independ-
ent experiments. Each set of experiments including a negative
control (EGY48) was carried out simultaneously and each sample
was measured in duplicate. As a positive control (pLex-B42), the
transformants expressing the known activation domain of B42
derived from bacteria fused to LexA were used. De¢nition of one
L-galactosidase unit as described in Fig. 1. (Note di¡erent scale for
LexH1C, LexH2C, and Lex-B42.)
Fig. 3. Growth dependency on transactivation of the Leu2 reporter
gene. The transformants of EGY48 with pLexH1 (top-left in both
A and B plates; producing the full-length Nm23-H1 fused to LexA
DBD), pLexH1N (middle-left; N-terminus of Nm23-H1), pLexH1C
(bottom-left; C-terminus of Nm23-H1), pLexH2 (top-right; full size
of Nm23-H2/PuF), pLexH2N (middle-right, N-terminus of Nm23-
H2), and pLexH2C (bottom-right, C-terminus of Nm23-H2) were
streaked on SD medium without uracil and histidine (plate A) and
lacking uracil, histidine, and leucine (plate B). The plates were incu-
bated at 30‡C for 5 days at the same conditions.
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Nm23-H2 monomer consists of four stranded antiparallel
L-sheets whose surfaces are partially covered by six K helices
[32]. The truncated C-terminal half used in this study con-
tained the regions of K3, K4, K5, and L4. Moreover, the C-
terminal half carried the active site of NDP kinase as well as
Kpn loop [9]. In order to test whether the structures of the
truncated C-terminal halves of Nm23 proteins could be main-
tained as the original topology, NDP kinase activities and
autophosphorylations in truncated proteins have been meas-
ured. It turned out that the C-terminal halves of both Nm23
isotypes still demonstrated the NDP kinase activities and also
retained the autophosphorylation capabilities (will be pub-
lished elsewhere). This indicated that the structure of the C-
terminal halves was relatively well maintained even after dele-
tion of the N-terminal halves.
Recently, Michelotti et al. reported that the full-length
Nm23-H1 and the Nm23-H2/PuF fused to the GAL4 DBD
failed to transactivate the bacterial chloramphenicol acetyl-
transferase (CAT) reporter gene using a transient transfection
assay [33]. Our data agreed well with the results of Michelotti
et al. However, these results disagreed to the earlier ¢nding of
Berberich and Postel where the myc-CAT expression could be
driven by Nm23-H2 in vivo [7]. The reason for such a dis-
crepancy is still not clear. However, both Michelotti’s and
Berberich’s papers suggested a possible involvement of a co-
factor(s) in in£uencing transcription by Nm23 proteins in
vivo. Since Nm23-H1 was known to form heteromers with
Nm23-H2 [17,19], the possibility of Nm23-H2 as a putative
cofactor in£uencing the transactivation capability of Nm23-
H1 was tested. However, our unpublished results excluded
such a possibility. In order to ¢nd other putative cofactors,
searching proteins interacting with Nm23 isotypes are cur-
rently underway using the yeast two-hybrid screening system.
The identities of these proteins might elucidate the mechanism
of Nm23 in transcriptional machinery.
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